Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially blocks α1A receptors in the prostate, bladder neck, and urethra, leading to smooth muscle relaxation and improved urinary flow.
## Primary Indications
* Signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsive therapy for distal ureteral calculi (ureterolithiasis).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily. May be increased to 0.8 mg daily if no response is observed after 2–4 weeks.
* **Ureteral Calculi (Off-label):** 0.4 mg orally once daily for up to 4 weeks.
## Pediatric Dosing
Safety and efficacy have not been established in the pediatric population. Its use is generally considered off-label and requires specialist pediatric urology oversight. No standard pediatric dose exists.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required for mild to moderate impairment. Use with caution in severe impairment (CrCl <10 mL/min).
* **Hepatic Impairment:** No dose adjustment required for mild to moderate impairment. Not studied in severe hepatic impairment.
* **CYP3A4/2D6 Inhibitors:** Limit dose to 0.4 mg if co-administered with strong inhibitors (e.g., ketoconazole, paroxetine).
## Contraindications
* Known hypersensitivity to tamsulosin.
* History of angioedema.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde ejaculation), rhinitis.
* **Serious:** Orthostatic hypotension (rare, but increased risk during initiation), syncope, intraoperative floppy iris syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **PDE-5 Inhibitors (e.g., sildenafil, tadalafil):** Increases risk of symptomatic hypotension. Should be stable on alpha-blocker therapy before starting PDE-5 inhibitors.
* **Strong CYP3A4 Inhibitors (e.g., ritonavir, clarithromycin):** May significantly increase tamsulosin plasma concentrations.
* **Antihypertensives:** May cause additive blood pressure lowering effects.
## Monitoring
* Monitor blood pressure periodically, especially upon initiation or dosage increase (risk of orthostasis).
* Assess symptom improvement via BPH score (e.g., IPSS).
* Query patient regarding scheduled cataract or glaucoma surgery.
## Clinical Pearls
* **Administration:** Administer 30 minutes after the same meal each day to ensure bioavailability and consistent clinical effect. Do not crush, chew, or open the capsule.
* **Syncope Risk:** The "first-dose effect" is less common with tamsulosin than non-selective alpha-blockers but is still possible; counsel patients to rise slowly from sitting or lying positions.
* **IFIS:** Tamsulosin is associated with Intraoperative Floppy Iris Syndrome. Patients should inform their ophthalmologist of current or prior use before cataract surgery.
***
**Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and specific patient contraindications before administering medication.
